Fulltext

Editorial: Model-informed drug development and evidence-based translational pharmacology

Zhao J 1 , Zhu X 2 , Tan S 3 , Chen C 3 , Kaddoumi A 4 , Guo XL 5 Show all authors , Lin YW 1 , Cheung SYA 6

Affiliations 

  • 1 Biomedicine Discovery Institute, Infection and Immunity Program and Department of Microbiology, Monash University, Melbourne, VIC, Australia
  • 2 Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China
  • 3 Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China
  • 4 Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL, United States
  • 5 Department of Pharmacology, School of Pharmaceutical Science, Shandong University, Jinan, China
  • 6 Integrated Drug Development, Certara, NJ, United States
Front Pharmacol, 2022;13:1086551.
PMID: 36578539 DOI: 10.3389/fphar.2022.1086551

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications